Authors:
Wafik S. El-Deiry, Joanne Xiu, Bora Lim, Angelique Scicchitano, Eileen Feeley, Harold A. Harvey, Nelson S. Yee
Background: Colorectal cancer (CRC) especially with KRAS/BRAF mutaFon (MT) is aggressive and has limited treatment opFons when metastaFc. We used a mulFplacorm molecular profiling (MP) approach to idenFfy potenFal treatments not typically considered for CRC in order to improve the management of this disease.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |